GlassScriptPhysician profile
Inti Fernandez
NPI 1659461101
$801.09
in general payments reported to CMS, 2019-2025
20 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.06 · 2020: $15.80 · 2021: $68.75 · 2022: $37.69 · 2023: $109 · 2024: $406 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.79 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $215.30 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $140.45 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $90.00 | 2024 | |
| Amgen INC. | $77.68 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $66.27 | 2024-2025 | Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.85 | 2019-2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $30.22 | 2019 | |
| Nestle Healthcare Nutrition INC. | $30.02 | 2021 | |
| Lilly USA, LLC | $29.77 | 2023-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $23.45 | 2025 | Verquvo |
| Exact Sciences Corporation | $19.50 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $17.14 | 2025 | |
| Amarin Pharma, INC. | $14.44 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inti Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.